FcRn antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11773168-B2
Application number	US-201816771147-A
Country	US
Kind code	B2
Filing date	Dec 13, 2018
Priority date	Dec 13, 2017
Publication date	Oct 3, 2023
Grant date	Oct 3, 2023

Abstract

The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

First claim

What is claimed is:

1. A method for treating or reducing the risk of developing a fetal and neonatal alloimmune and/or autoimmune disorder comprising administering to a pregnant woman a composition comprising an antibody comprising a light chain having the amino acid sequence of SEQ ID NO:19 and a heavy chain having the amino acid sequence of SEQ ID NO:24, wherein the composition is administered to the pregnant woman from about gestational week 13 to about gestational week 35.

2. The method of claim 1 , wherein the antibody is administered at a dose per administration and is based on the weight of the pregnant woman at first dosing and is not adjusted upward based on weight gain by the pregnant woman.

3. The method of claim 1 , wherein the antibody is administered at a dose per administration and is based on the weight of the pregnant woman at first dosing and is adjusted upward based on weight gain by the pregnant woman.

4. The method of claim 1 , wherein the composition is administered at least every other week.

5. The method of claim 1 , wherein the composition is administered every other week.

6. The method of claim 1 , wherein the composition is administered at least every week.

7. The method of claim 1 , wherein IVIG is administered to the pregnant woman after cessation of administration of the antibody and prior to birth.

8. The method of claim 7 , wherein IVIG is administered to the pregnant woman 40-100 hrs prior to birth.

9. The method of claim 7 , wherein the IVIG is administered at a dose of 200 mg/kg-1000 mg/kg based on the weight of the pregnant woman.

10. The method of claim 1 , wherein the composition is administered from gestational week 13 to gestational week 35.

11. The method of claim 1 , wherein the composition is administered from gestational week 14 to gestational week 35.

12. The method of claim 1 , wherein the composition is administered from gestational week 15 to gestational week 35.

13. The method of claim 1 , wherein the composition is administered from gestational week 16 to gestational week 35.

Assignees

• Momenta Pharmaceuticals Inc

Inventors

• Ling Leona E
• Nix Darrell
• Cilfone Nicholas A

Classifications

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• C07K16/283 Primary

  against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851) · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title